Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2024 (Report dated April 15, 2024)
Context: The filing reports the submission of final clinical trial data to the U.S. Food and Drug Administration (FDA) for marketing authorization to treat early-stage breast cancer using the ICE3 cryoablation system.
Key Financial Metrics
This Form 6-K filing does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The document focuses exclusively on clinical trial results and regulatory submissions.
Material Changes and Clinical Results
The filing highlights the following material developments regarding the ICE3 Breast Cancer Cryoablation Trial:
- Patient and Physician Satisfaction: 100% satisfaction rate reported.
- Recurrence Free Rate: 96.3% recurrence-free rate achieved.
- Regulatory Action: Data has been submitted to the FDA for marketing authorization.
- Conference Presentation: Topline data was presented at the ASBrS 2024 Annual Meeting.
Guidance, Outlook, and Risks
Outlook: The company is pursuing FDA marketing authorization for early-stage breast cancer treatment based on the submitted data.
Forward-Looking Statements: The press release incorporated by reference contains forward-looking statements regarding the regulatory process and commercial potential.
Risks: The filing text does not explicitly detail specific risks or contingencies beyond the standard incorporation of forward-looking statement disclaimers found in the referenced press release.
Investor Verification Checklist
- Verify the status of the FDA review process for the submitted ICE3 breast cancer data.
- Review the full text of the press release (Exhibit 99.1) for detailed methodology and limitations of the 96.3% recurrence-free rate.
- Monitor upcoming regulatory decisions or requests for additional data from the FDA.
- Check subsequent filings for any updates on the commercialization timeline or partnership discussions related to the breast cancer indication.